+

WO1999029279A3 - Survie a long terme et regeneration de neurones du systeme nerveux central - Google Patents

Survie a long terme et regeneration de neurones du systeme nerveux central Download PDF

Info

Publication number
WO1999029279A3
WO1999029279A3 PCT/US1998/025663 US9825663W WO9929279A3 WO 1999029279 A3 WO1999029279 A3 WO 1999029279A3 US 9825663 W US9825663 W US 9825663W WO 9929279 A3 WO9929279 A3 WO 9929279A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
central nervous
regeneration
long
cns
Prior art date
Application number
PCT/US1998/025663
Other languages
English (en)
Other versions
WO1999029279A2 (fr
Inventor
Barbara A Barres
Original Assignee
Univ Leland Stanford Junior
Barbara A Barres
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Barbara A Barres filed Critical Univ Leland Stanford Junior
Priority to AU19965/99A priority Critical patent/AU1996599A/en
Publication of WO1999029279A2 publication Critical patent/WO1999029279A2/fr
Publication of WO1999029279A3 publication Critical patent/WO1999029279A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une culture in vitro de cellules neuronales du système nerveux central (CNS). Cette culture est caractérisée par l'absence de cellules nourricières ou d'un milieu conditionné par des cellules nourricières, par un milieu de culture sensiblement exempt de sérum et par une viabilité améliorée. Elle concerne également des procédés servant à cultiver des cellules purifiées du système nerveux central dans des conditions déterminées pendant des périodes prolongées, ainsi que des procédés servant à favoriser la régénération et la survie de neurones détériorés du système nerveux central in vivo, et une composition pharmaceutique correspondante.
PCT/US1998/025663 1997-12-05 1998-12-03 Survie a long terme et regeneration de neurones du systeme nerveux central WO1999029279A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19965/99A AU1996599A (en) 1997-12-05 1998-12-03 Long-term survival and regeneration of central nervous system neurons

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98552197A 1997-12-05 1997-12-05
US08/985,521 1997-12-05

Publications (2)

Publication Number Publication Date
WO1999029279A2 WO1999029279A2 (fr) 1999-06-17
WO1999029279A3 true WO1999029279A3 (fr) 1999-10-21

Family

ID=25531561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/025663 WO1999029279A2 (fr) 1997-12-05 1998-12-03 Survie a long terme et regeneration de neurones du systeme nerveux central

Country Status (2)

Country Link
AU (1) AU1996599A (fr)
WO (1) WO1999029279A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245564B1 (en) 1997-01-23 2001-06-12 Cornell Research Foundation, Inc. Method for separating cells
US8263402B1 (en) 1998-10-19 2012-09-11 Cornell Research Foundation, Inc. Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
WO2001046384A2 (fr) 1999-12-23 2001-06-28 Cornell Research Foundation, Inc. Technique d'isolation et de purification de cellules neuronales multipotentes progenitrices et cellules neuronales multipotentes progenitrices
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US7150989B2 (en) 2001-08-10 2006-12-19 Cornell Research Foundation, Inc. Telomerase immortalized neural progenitor cells
WO2003070189A2 (fr) 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Amelioration de la neurogenese induite par neurotrophine au moyen de cellules souches neurales endogenes par surexpression parallele du facteur neurotrophique derive du cerveau et d'un inhibiteur d'une proteine morphogenetique osseuse pro-gliogenique
US7312025B2 (en) 2002-07-12 2007-12-25 University Of Washington Methods and systems for extended in vitro culture of neuronal cells
WO2007048846A1 (fr) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Utilisation de composes chelateurs du fer, composes augmentant l'adenosine monophosphate cyclique ou combinaisons de ces substances pour traiter des lesions axonales dans le systeme nerveux central
WO2007073151A1 (fr) * 2005-12-21 2007-06-28 Stichting Katholieke Universiteit Équivalents de peau psoriasique
EP2076124A4 (fr) 2007-04-20 2011-08-03 Acucela Inc Composés dérivés de styrényle pour traiter des maladies et des troubles ophtalmiques
AU2008271051C1 (en) 2007-06-29 2012-10-04 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
EP2091955B1 (fr) 2007-10-05 2016-12-07 Acucela, Inc. Alcoxyphénylpropylamines pour le traitement de la dégénérescence maculaire liée à l'âge
WO2013109991A1 (fr) 2012-01-20 2013-07-25 Acucela Inc. Composés hétérocycliques substitués pour le traitement d'une maladie
JP2016512528A (ja) 2013-03-12 2016-04-28 アクセラ インコーポレイテッド 眼疾患及び眼障害を治療するための置換された３−フェニルプロピルアミン誘導体
CN115404219B (zh) * 2022-09-09 2023-10-27 中国医学科学院医学生物学研究所 一种树鼩视网膜神经节细胞的分离培养方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5584885A (en) * 1994-04-28 1996-12-17 Seckel; Brooke R. Nerve regeneration chamber
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
US5584885A (en) * 1994-04-28 1996-12-17 Seckel; Brooke R. Nerve regeneration chamber

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYDEL R E, GREENE L A: "CAMP ANALOGS PROMOTE SURVIVAL AND NEURITE OUTGROWTH IN CULTURES OF RAT SYMPATHETIC AND SENSORY NEURONS INDEPENDENTLY OF NERVE GROWTH FACTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 85, 1 February 1988 (1988-02-01), US, pages 1257 - 1261, XP002919694, ISSN: 0027-8424, DOI: 10.1073/pnas.85.4.1257 *

Also Published As

Publication number Publication date
WO1999029279A2 (fr) 1999-06-17
AU1996599A (en) 1999-06-28

Similar Documents

Publication Publication Date Title
WO1999029279A3 (fr) Survie a long terme et regeneration de neurones du systeme nerveux central
AU2154200A (en) Low oxygen culturing of central nervous system progenitor cells
HK1019233A1 (en) Animal cells and processes for the replication of influenza viruses
AU4330597A (en) Serum-free mammalian cell culture medium, and uses thereof
AU7735196A (en) In vitro chondrogenic induction of human mesenchymal stem cells
NZ288467A (en) In vitro method for culturing cartilage tissue by culturing stromal cells in the presence of growth factors
TW334432B (en) Tricyclic amide and urea compounds
AU5886000A (en) Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells
IL130281A0 (en) Serum-free cell culture media
WO1997012960A3 (fr) Support solide de culture de cellules et en particulier de cellules hepatiques, reacteur biologique utilisant ledit support et leur emploi dans un systeme de foie bio-artificiel
AU2260097A (en) Hematopoietic cell culture nutrient supplement
AU6311099A (en) Serum-free medium for culturing animal cells
AU3969689A (en) Bio-reactor cell culture process
AU2387795A (en) Culture medium for maintaining viability of mammalian cells
CA2146734A1 (fr) Methode pour la sous-culture a long terme de cellules de papilles dermiques
AU7131696A (en) Rotating solar photo bioreactor for use in the production of algal biomass from gases, in particular CO2-containing gases
ATE364408T1 (de) Verfahren zur kultivierung von knorpelersatz und biomatrix nach diesem verfahren hergestellt
AU6571700A (en) Enzymatic synthesis of deoxyribonucleosides
AU6937596A (en) Neural transplantation using pluripotent neuroepithelial cells
AU7443996A (en) Method for ex vivo proliferation and differentiation of adult pancreatic islet cells, media useful therefor and uses thereof
AU2777097A (en) Process and carrier for the production of isomaltulose by immobilized micro-organisms
HUP0000868A3 (en) Solid culture medium for microorganisms, process for its preparation, and use
AU6766994A (en) Culture media additives for hollow fiber bioreactors
AU2001278700A1 (en) Method of culturing human chondrocytes
AU5391886A (en) Method and device for the in vitro culture of plant cells and organs, as well as for the micropropagation and regeneration of complete plants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载